Results 171 to 180 of about 38,769 (305)

Nationwide Real‐World Retrospective Study of Oral Semaglutide Use in Adults Living With Type 2 Diabetes in Finland

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim This Finnish nationwide retrospective 'real‐world' study evaluated the effects of oral semaglutide on glycaemic control, body weight, lipid profile, and liver enzymes in adults living with type 2 diabetes (T2D) and naïve to any GLP‐1 receptor agonists in Finland.
Atte Vaden, Mari Lahelma, Lalli Nurmi, Eija Heikkilä, Hannu Vessari, Hanne Luoto, Tero Saukkonen, Leo Niskanen   +7 more
wiley   +1 more source

Is thirst the missing physiological link between SGLT2 inhibitors and reduced nephrolithiasis risk? [PDF]

Clin Kidney J
Lombardi M, Beltrami P, Martini B.
europepmc   +1 more source

Cost‐Effectiveness of NT‐proBNP–Guided Cardiovascular Screening in Chinese Adults With Type 2 Diabetes: Real‐World Evidence From the Hong Kong Diabetes Biobank

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Heart failure (HF) is among the most costly and prevalent complications of type 2 diabetes (T2D), with annual incremental healthcare costs reaching US$12800 in Hong Kong. We evaluated the cost‐effectiveness of NT‐proBNP‐guided cardiovascular risk stratification to guide cardioprotective treatment. Materials and Methods We developed a four‐
Abby Q. Y. Li, Benjamin Yarnoff, Claudia H. T. Tam, Juliana C. N. Chan, Ronald C. W. Ma, Juliana N. M. Lui, Hong Kong Diabetes Biobank Study Group   +6 more
wiley   +1 more source

GLP1-agonists and SGLT2 inhibitors in the perioperative setting

The use of GLP1-agonists and SGLT2 inhibitors among inpatients increases due to their favorable metabolic, cardiovascular, and renal effects. However, there are concerns regarding their perioperative safety, because of delayed gastric emptying associated
de Galan, Bastiaan E, Hulst, Abraham H, Hermanides, Jeroen, Stobbe, Ayla Y, Oosterom-Eijmael, Maartina J P, Siegelaar, Sarah E   +5 more
core   +1 more source

Targeting metabolism to protect fertility and healthy pregnancy with SGLT2 inhibitors and GLP-1RAs. [PDF]

Curr Opin Physiol
Flanary SM, Yoshida K, Alejandro EU, Townsend D.   +3 more
europepmc   +1 more source

SGLT2 inhibitors: the story continues to unfold [PDF]

European Heart Journal, 2021
openaire   +2 more sources

Empagliflozin Versus Dapagliflozin and Urogenital Adverse Events in Type 2 Diabetes: A Target Trial Emulation

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Urogenital adverse events are common with sodium‐glucose co‐transporter 2 inhibitors (SGLT2i) and may influence treatment decisions. Variations in SGLT2i selectivity, potency and effects on renal glucose excretion could lead to differences in safety profiles. We compared the risks of urinary tract infection (UTI), genital tract infection (
Christine Ljungberg, Kasper Bonnesen, Morten Schmidt, Christina Vandenbroucke‐Grauls, Michael Dalager‐Pedersen, Henrik Toft Sørensen, Mette Nørgaard, Reimar Wernich Thomsen   +7 more
wiley   +1 more source

SGLT2 inhibitors and bone health in CKD. [PDF]

Clin Kidney J
Haarhaus M.
europepmc   +1 more source

Combining Sodium–Glucose Co‐Transporter‐2 Inhibitor Plus Glucagon‐Like Peptide‐1 Receptor Agonist for Glucose‐Lowering in Type 2 Diabetes: Effects of Drug Initiation Sequence on Kidney Function in Real‐World Clinical Practice (CombiKid Study)

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Sodium–glucose co‐transporter 2 inhibitors (SGLT2is) and glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have separately shown renoprotective effects in clinical trials in people with type 2 diabetes. It is unclear whether combining these agents produces incremental kidney outcome benefits. Materials and Methods Retrospective cohort
William Hinton, Mark Joy, Anna K. Forbes, Martin B. Whyte, José M. Ordóñez‐Mena, Xuejuan Fan, Filipa Ferreira, Bernardo Meza‐Torres, Neil Munro, Simon de Lusignan, David C. Wheeler, Michael D. Feher   +11 more
wiley   +1 more source

Multi‐Parametric Magnetic Resonance Imaging to Assess Empagliflozin Effect on the Kidneys in People With Type 2 Diabetes Mellitus: A Pilot Clinical Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Empagliflozin is renoprotective in Type 2 diabetes mellitus (T2DM). Our primary aim was to assess empagliflozin's effect on glomerular filtration rate and renal vascular resistance using multiparametric MRI (MpMRI). Our secondary aim was to assess the impact of empagliflozin on additional MpMRI‐derived metrics including markers of tissue ...
Ruth P. Lim, Salma Qassin, Lucy McKenna, Emma Hornsey, Dominic Italiano, Leonid Churilov, Richard J. MacIsaac, Jas‐mine Seah, Elif I. Ekinci, The Austin EMPA‐MRI Study Group   +9 more
wiley   +1 more source